Who are LY900003's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NovoHelisen Depot, Benaglutide Injection, GLP-1 RAs, Continue GLP/GIP, dulaglutide injection, Exenatide twice daily (BID).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ly900003.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

LY900003 — Competitive Intelligence Brief

LY900003 (LY900003) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Endocrinology.

phase 3 GLP-1 receptor agonist GLP-1R Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

LY900003 (LY900003) — Eli Lilly and Company. LY900003 is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose and promote weight loss.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LY900003 TARGET	LY900003	Eli Lilly and Company	phase 3	GLP-1 receptor agonist	GLP-1R
NovoHelisen Depot	NovoHelisen Depot	Wroclaw Medical University	marketed	GLP-1 receptor agonist	GLP-1R
Benaglutide Injection	Benaglutide Injection	The Affiliated Hospital of Qingdao University	marketed	GLP-1 receptor agonist	GLP-1R
GLP-1 RAs	GLP-1 RAs	Shanghai 10th People's Hospital	marketed	GLP-1 receptor agonist	GLP-1R
Continue GLP/GIP	Continue GLP/GIP	The Cleveland Clinic	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR
dulaglutide injection	dulaglutide injection	First Affiliated Hospital of Zhejiang University	marketed	GLP-1 receptor agonist	GLP-1R
Exenatide twice daily (BID)	Exenatide twice daily (BID)	Eli Lilly and Company	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LY900003 — Competitive Intelligence Brief. https://druglandscape.com/ci/ly900003. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab